Literature DB >> 21954089

High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain).

María Sierra1, Isabel González-Aramburu, Pascual Sánchez-Juan, Coro Sánchez-Quintana, José Miguel Polo, José Berciano, Onofre Combarros, Jon Infante.   

Abstract

The frequency and penetrance of the LRRK2 G2019S mutation varies considerably in different Parkinson disease (PD) populations. This information is essential both for clinical purposes and genetic counseling. The objective of this study was to estimate the prevalence and penetrance of the G2019S mutation of the LRRK2 gene in a small region in northern Spain (Cantabria). The G2019S mutation was tested in 367 consecutive patients with PD attended as outpatients in a tertiary Hospital in Northern Spain, and 126 at-risk family members of probands were also investigated for G2019S mutation and disease status. The gene penetrance was estimated in terms of cumulative age-specific incidence of PD by the Kaplan-Meier method. Thirty-two PD patients (8.7%) carried the G2019S mutation. Penetrance estimation of the G2019S mutation was 2% at 50 years, 12% at 60 years, 26% at 70 years, and 47% at 80 years. The frequency of the G2019S mutation of the LRRK2 gene in PD patients from Cantabria is among the highest reported so far after North African Arabs and Ashkenazi Jews. At the age of 80 years only one-half of G2019S mutation carriers manifest motor symptoms of PD.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21954089     DOI: 10.1002/mds.23965

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  19 in total

1.  Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

Authors:  Ilir Agalliu; Roberto A Ortega; Marta San Luciano; Anat Mirelman; Claustre Pont-Sunyer; Kathrin Brockmann; Dolores Vilas; Eduardo Tolosa; Daniela Berg; Bjørg Warø; Amanda Glickman; Deborah Raymond; Rivka Inzelberg; Javier Ruiz-Martinez; Elisabet Mondragon; Eitan Friedman; Sharon Hassin-Baer; Roy N Alcalay; Helen Mejia-Santana; Jan Aasly; Tatiana Foroud; Karen Marder; Nir Giladi; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2019-07-26       Impact factor: 10.338

2.  Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Authors:  Ilir Agalliu; Marta San Luciano; Anat Mirelman; Nir Giladi; Bjorg Waro; Jan Aasly; Rivka Inzelberg; Sharon Hassin-Baer; Eitan Friedman; Javier Ruiz-Martinez; Jose Felix Marti-Masso; Avi Orr-Urtreger; Susan Bressman; Rachel Saunders-Pullman
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

3.  Early-onset pathologically proven multiple system atrophy with LRRK2 G2019S mutation.

Authors:  Giulietta Maria Riboldi; Jose-Alberto Palma; Etty Cortes; Megan A Iida; Tamjeed Sikder; Brooklyn Henderson; Towfique Raj; Ruth H Walker; John F Crary; Horacio Kaufmann; Steven Frucht
Journal:  Mov Disord       Date:  2019-05-11       Impact factor: 10.338

Review 4.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

Review 5.  Genetic determinants of neuronal vulnerability to apoptosis.

Authors:  Angeles Almeida
Journal:  Cell Mol Life Sci       Date:  2012-06-14       Impact factor: 9.261

6.  Genetic Modifiers of Neurodegeneration in a Drosophila Model of Parkinson's Disease.

Authors:  Sierra Lavoy; Vinita G Chittoor-Vinod; Clement Y Chow; Ian Martin
Journal:  Genetics       Date:  2018-06-15       Impact factor: 4.562

7.  Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease.

Authors:  María Sierra; Isabel Martínez-Rodríguez; Pascual Sánchez-Juan; Isabel González-Aramburu; Mikel Jiménez-Alonso; Antonio Sánchez-Rodríguez; José Berciano; Ignacio Banzo; Jon Infante
Journal:  Neurology       Date:  2017-07-05       Impact factor: 9.910

8.  Coding mutations in SORL1 and Alzheimer disease.

Authors:  Badri N Vardarajan; Yalun Zhang; Joseph H Lee; Rong Cheng; Christopher Bohm; Mahdi Ghani; Christiane Reitz; Dolly Reyes-Dumeyer; Yufeng Shen; Ekaterina Rogaeva; Peter St George-Hyslop; Richard Mayeux
Journal:  Ann Neurol       Date:  2015-02       Impact factor: 10.422

9.  Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers.

Authors:  Claustre Pont-Sunyer; Alex Iranzo; Carles Gaig; Ana Fernández-Arcos; Dolores Vilas; Francesc Valldeoriola; Yaroslau Compta; Ruben Fernández-Santiago; Manel Fernández; Angels Bayés; Matilde Calopa; Pilar Casquero; Oriol de Fàbregues; Serge Jaumà; Victor Puente; Manel Salamero; Maria José Martí; Joan Santamaría; Eduard Tolosa
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

Review 10.  TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.

Authors:  Helen Ling; Eleanna Kara; Rina Bandopadhyay; John Hardy; Janice Holton; Georgia Xiromerisiou; Andrew Lees; Henry Houlden; Tamas Revesz
Journal:  Neurobiol Aging       Date:  2013-05-09       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.